1. 代表中華民國癌症醫學會(TOS，Taiwan Oncology Society)出席訂定國際（全亞洲）「癌症治療指引」（Pan-Asian adapted ESMO consensus guidelines），目前共發表6篇大腸癌(Ann Oncol. 2018; 29(1): 44、Ann Oncol 2021; 32(12):1496、ESMO Open 2023;8(3):101558.)、胃癌(Ann Oncol. 2019;30(1):19)、食道癌(Ann Oncol. 2019 ; 30(1):34)、全癌(跨癌別)(agnostic) MSI/NTRK (Ann Oncol 2020;31(7):861)。
2. 積極參與“國際多中心大規模臨床試驗”，推動消化道腫瘤抗癌新藥獲準。 以胃癌、大腸癌為例：
◎ATTRACTION-2 phase III trial: nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens. (Lancet 2017;390:2461-2471), leading to TFDA approval.
◎KEYNOTE-061 phase III trial: pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer. (Lancet 2018;392:123-133).
◎CONCUR phase III trial: regorafenib monotherapy in asian patients with previously treated metastatic colorectal cancer (Lancet Oncol 2015;16:619-29). ◎KEYNOTE-177 phase III trial: pembrolizumab in microsatellite-instability–high advanced colorectal cancer (N Engl J Med. 2020;383:2207-2218).
3. 與日本癌症醫院東病院(National Cancer Center East)合作進行大腸癌患者術後循環腫瘤DNA(ctDNA)之大規模前瞻性IIT研究。
◎GALAXY study：研究預計招募5,000名患者，目前已招募超過3,000名患者。初步報告已陸續發表在2021 annual meeting of European Society for Medical Oncology (ESMO), the 2022 American Society of Clinical Oncology (ASCO) GI cancers symposium, the 2023 annual meeting of Japanese Society of Medical Oncology (JSMO), the 2023 annual meeting of ASCO, and the 2024 annual meeting of ASCO.
4. 近五年獲獎：
(1) 2022，臺大醫院「研究卓越團隊獎」 — 消化道癌臨床試驗團隊
(2) 2023，徐千田癌症研究傑出獎
(3) 2023，元大文教基金會「醫師科學家獎」（葉坤輝教授/梁逸歆醫師 － 師生同時獲獎）